Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: a joint analysis of the multicenter, observational, real-world French PEMI-BIL and Italian PEMI-REAL cohort studies
-
Published:2024-02
Issue:
Volume:
Page:113587
-
ISSN:0959-8049
-
Container-title:European Journal of Cancer
-
language:en
-
Short-container-title:European Journal of Cancer
Author:
Parisi AlessandroORCID, Delaunay Blandine, Pinterpe GiadaORCID, Hollebecque AntoineORCID, Blanc Jean Frederic, Bouattour MohamedORCID, Assenat Eric, Ben Abdelghani MeherORCID, Sarabi Matthieu, Niger Monica, Vivaldi CaterinaORCID, Mandalà MarioORCID, Palloni AndreaORCID, Bensi Maria, Garattini Silvio Ken, Tougeron DavidORCID, Combe Pierre, Salati Massimiliano, Rimini Margherita, Cella Chiara Alessandra, Tucci Marco, Diana AnnaORCID, Mori Elena, Longarini Raffaella, Artru PascalORCID, Roth GaelORCID, Evesque Ludovic, Vienne Agathe, Turpin AnthonyORCID, Hiret Sandrine, Bourgeois Vincent, Herve Camille, Paulon RodolpheORCID, Stacoffe Marion, Malka DavidORCID, Neuzillet CindyORCID, Edeline JulienORCID, Lievre Astrid, Guimbaud RosineORCID, Tchapda Marie Christelle Pajiep, Rimassa LorenzaORCID, Giampieri Riccardo, Valle JuanORCID, Berardi Rossana, Fares Nadim
Subject
Cancer Research,Oncology
Reference29 articles.
1. ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up;Vogel;Ann Oncol,2023 2. Survival in patients with primary liver cancer, gallbladder and extrahepatic biliary tract cancer and pancreatic cancer in Europe 1999–2007: Results of EUROCARE-5;Lepage;Eur J Cancer,2015 3. ABC-02 Trial Investigators. cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer;Valle;N Engl J Med,2010 4. A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1;Oh;NEJM Evid,2022 5. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial;Kelley;The Lancet. 3 juin,2023
|
|